Andrew J. Norris

Dr. Andrew Norris has a varied background in both business and the technology sector. Dr. Norris co-founded BCN Biosciences, with the aim of creating novel approaches to the development of therapeutics in oncology and supportive care. Currently he oversees all research at BCN Biosciences and holds a research faculty position at The University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior. He has also served as a consultant to many life sciences and healthcare companies. Dr. Norris technical background is formally in pharmacology and biochemistry with an emphasis in synthetic chemistry. He has worked with a variety of disciplines spanning across executive level business teams to chemistry, virology, immunology, oncology, and the process of drug developments. He has lead programs in the development of countermeasures for radiation toxicity for more than 10 years in collaboration with NIH, University of California, and Kansas University Medical center. He has also held key roles in work with the United States government Biomedical Advanced Research and Development Authority (BARDA) and has coordinated the activity of multiple centers (UCLA, CitoxLab North America (now Charles Rivers Laboratories, Cambridge Major Laboratories (now Alcami Corporation etc.), as well as served as the PI multiple contracts and grants with the National Cancer Institute, the National institutes of Allergy and Infectious Diseases (NIAID) among others. Historically, Dr. Norris has also given guidance to faculty and researchers alike on multiple levels of the process of preclinical drug development to empower the intention of basic research is effectively translated into useful therapies.